[Signal Transduction and Targeted Therapy] Researchers uncovered a bidirectional crosstalk between Oncostatin M receptor (OSMR) and tmCLIC1 in glioblastoma, essential for fueling its malignant growth.

[Cell Stem Cell] Scientists tested whether ferroptosis-related vulnerability contributes to the regulation of hippocampal neural precursor cells and their progeny.

[Nature Communications] Using a human telencephalic organoid model, investigators performed comprehensive proteomic profiling of neural stem/progenitor cell cilia and found enrichment in GTPase signaling.

[Nature Communications] Researchers combined spatial transcriptomics with region-resolved endothelial single-cell RNA sequencing in the postnatal mouse brain to map cortical and thalamic neurovascular unit communication dynamics.

[Autophagy] Scientists demonstrated that, contrary to its well-established pro-apoptotic role, TRP53 acts as a survival factor that protects ahNSCs from stress-induced autophagic cell death.

[Analytical Chemistry] Investigators developed a novel fluorescent probe, QM-SO3H, that targets the wild-type IDH1 enzyme to enable intraoperative navigation for glioblastoma.

[Cancer Cell International] The authors synthesize emerging evidence that T cell immunoglobulin and mucin-domain containing-3 operates dually: on one edge, it acts as an important contributor to immune exhaustion, suppressing T cell, natural killer cell, and dendritic cell function within the AML niche.

[Brain Cancer Canada (Globe Newswire)] Brain Cancer Canada awards $50,000 to an exciting research project led by Dr Ian Lorimer and his team at Ottawa Hospital Research Institute. The project titled “Improving glioblastoma immunotherapy by selectively blocking macrophage activity” explores a new way of possibly treating glioblastoma and might soon pave the way for a clinical trial.

[BioRestorative Therapies, Inc. ] BioRestorative Therapies, Inc. announced that the last patient has been dosed in its fully enrolled Phase II clinical trial evaluating BRTX-100 for the treatment of chronic lumbar disc disease, completing treatment administration in the Company’s lead clinical program.

[TriCelX, Inc.] TriCelX, Inc. has submitted a Phase I/II Investigational New Drug application to the US FDA for XytriX™ — its proprietary allogeneic UC-MSC biotherapeutic, ethically sourced from donated human birth tissue — for adults with confirmed or probable Chronic Traumatic Encephalopathy.

[Neurology] In this randomized, double-blind, placebo-controlled Phase I/II trial, patients with progressive multiple sclerosis enrolled at four Norwegian tertiary hospitals received a single intrathecal injection of autologous bone marrow–derived MSCs in a crossover design.

[Arteriosclerosis Thrombosis and Vascular Biology] This cross-species analysis revealed a conserved mesenchymal cell continuum, spanning contractile smooth muscle cells to extracellular matrix-producing fibroblast-like cells, that was stable across species and vascular beds.